Impact of Chronic Pulmonary Aspergillosis (CPA) on Health Status and Well-being

To develop and validate a novel disease-specific questionnaire for measuring HRQoL in patients with Chronic Pulmonary Aspergillosis (CPA-HAQ) for use in clinical research, including clinical trials.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Chronic Pulmonary Aspergillosis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ninewells Hospital & Medical School, Dundee, United Kingdom

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All patients >/= 18 years old and able to provide informed consent
Patients with a diagnosis of chronic pulmonary aspergillosis
To speak and understand English
Able to provide informed consent

Treatment and study plan

Primary outcomes

Impact of Chronic Pulmonary Aspergillosis (CPA) on health status and Well-being.

Time frame: 30 months

To develop and validate a novel disease-specific health-related quality of life (HRQoL) measure in chronic pulmonary aspergillosis (CPA): The Chronic Pulmonary Aspergillosis Health Assessment Questionnaire (CPA-HAQ)

Secondary outcomes

Impact of Chronic Pulmonary Aspergillosis (CPA) on health status and Well-being.

Time frame: 30 months

Testing the usability of a newly developed CPA-HAQ measure.
Impact of Chronic Pulmonary Aspergillosis (CPA) on health status and Well-being.

Time frame: 30 months

Correlating how HRQoL outcomes relate to existing disease prognostic markers.

Study contacts

Contact information is provided by the study sponsor or research team.

Anand Shah, PhD

CONTACT

[email protected]

Dareen Marghlani, MSc

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Imperial College London

Other

Collaborators

Manchester University NHS Foundation Trust
Tayside Medical Science Centre

Registry information

Acronym: CAPSULE

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2026
First posted: Mar 20, 2025
Registry last updated: Mar 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting